S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Is this AI's biggest breakthrough to date? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Is this AI's biggest breakthrough to date? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Is this AI's biggest breakthrough to date? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Is this AI's biggest breakthrough to date? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN? (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

$5.80
+0.11 (+1.93%)
(As of 02/23/2024 ET)
Today's Range
$5.61
$5.81
50-Day Range
$5.24
$6.21
52-Week Range
$1.24
$6.30
Volume
688,508 shs
Average Volume
1.14 million shs
Market Capitalization
$1.78 billion
P/E Ratio
96.67
Dividend Yield
N/A
Price Target
$5.40

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
6.9% Downside
$5.40 Price Target
Short Interest
Healthy
2.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of Amneal Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.04%
From $0.49 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.37 out of 5 stars

Medical Sector

740th out of 943 stocks

Pharmaceutical Preparations Industry

338th out of 429 stocks


AMRX stock logo

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock Price History

AMRX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Amneal to Participate at Upcoming Investor Conference
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Top 3 Pharma Stocks With Bullish Momentum
Knight Therapeutics Inks License Agreement With Amneal Pharma For IPX203
Amneal Announces Move to Nasdaq
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/05/2023
Today
2/24/2024
Next Earnings (Confirmed)
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMRX
Previous Symbol
NASDAQ:AMRX
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.40
High Stock Price Target
$8.00
Low Stock Price Target
$3.00
Potential Upside/Downside
-6.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-129,990,000.00
Pretax Margin
1.49%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$1.45 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
225,126,000
Market Cap
$1.78 billion
Optionable
Optionable
Beta
1.34
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives















AMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price target for 2024?

5 brokerages have issued 1 year target prices for Amneal Pharmaceuticals' shares. Their AMRX share price targets range from $3.00 to $8.00. On average, they expect the company's stock price to reach $5.40 in the next year. This suggests that the stock has a possible downside of 6.9%.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2024?

Amneal Pharmaceuticals' stock was trading at $6.07 at the start of the year. Since then, AMRX shares have decreased by 4.4% and is now trading at $5.80.
View the best growth stocks for 2024 here
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024.
View our AMRX earnings forecast
.

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Friday, March 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced its earnings results on Friday, May, 5th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.09 by $0.01. The company earned $557.54 million during the quarter, compared to analysts' expectations of $555 million. Amneal Pharmaceuticals had a trailing twelve-month return on equity of 109.82% and a net margin of 0.43%. During the same period in the previous year, the company earned $0.10 earnings per share.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, January, 10th. The company provided EPS guidance of $0.51-0.58 for the period, compared to the consensus earnings per share estimate of $0.59. The company issued revenue guidance of $2.37-2.42 billion, compared to the consensus revenue estimate of $2.41 billion.

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.45%), Rubric Capital Management LP (2.61%), Dimensional Fund Advisors LP (0.92%), Nantahala Capital Management LLC (0.76%), Nuveen Asset Management LLC (0.64%) and Charles Schwab Investment Management Inc. (0.43%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMRX) was last updated on 2/25/2024 by MarketBeat.com Staff